Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL3235279 | 0.97 | ALDH1A1 (0.51) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| Ethylene SCHEMBL1721460 | 0.82 | MEN1 (0.41) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL23722370 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL30919794 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL23231710 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL9616977 | 0.80 | ALDH1A1 (0.54) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL4193592 | 0.79 | ALDH1A1 (0.52) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL743773 | 0.78 | MEN1 (0.35) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL9813163 | 0.78 | MEN1 (0.39) | MEN1KMT2ACYP2C9CYP3A4 | |
| SCHEMBL613248 | 0.77 | MEN1 (0.63) | ALDH1A1POLBMEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2580208-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8450304-B2 | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-28 | — | — | US | disclosed |
| US-8436023-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-05-07 | — | — | US | disclosed |
| EP-2580208-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-04-17 | — | — | EP | disclosed |
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-15 | — | — | US | disclosed |
| WO-2011156554-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-15 | — | — | WO | disclosed |
| EP-2376475-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | Janssen Pharmaceutica N.V. (BE) | 2011-10-19 | — | — | EP | disclosed |
| CN-102153539-A | 3-aminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORP | 2011-08-17 | — | — | CN | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306592-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | ALDH1A1 544/4885LMNA 3939/4885POLB 4407/4885 |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | ALDH1A1 426/4885LMNA 4677/4885POLB 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.